---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-107052"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2024-10-08T23:59:59+00:00"
generated_at: "2026-05-30T18:13:31.655272+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics reports preclinical GT-02287 data showing disease-modifying potential in Parkinson's models

## Summary
- GT-02287 rescued motor and cognitive deficits in GBA1 and idiopathic PD models; effects persisted >1 week after drug withdrawal.
- GT-02287 improved mitochondrial function and reduced α-synuclein aggregation in GBA1-PD in vitro and in vivo models.
- GT-02287 reduced Tau accumulation in GBA1-mutant and wild-type cell lines, suggesting potential for Alzheimer's disease.
- Delayed GT-02287 administration restored motor function to control levels and reduced neurodegeneration markers (NfL).

## SEC filing metadata
- accession: 0001104659-24-107052
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2024-10-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465924107052/0001104659-24-107052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465924107052/tm2425756d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-107052
- JSON: https://secwatch.observer/filing/0001104659-24-107052.json
- Plain text: https://secwatch.observer/filing/0001104659-24-107052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.